UCB’s Cimzia BLA Could Provide First Subcutaneous Injection For Crohn’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
UCB is touting the "greater convenience" of its Cimzia subcutaneous injection for Crohn's disease compared to Johnson & Johnson's intravenous injection Remicade
You may also be interested in...
Crohn’s Candidates Capitalize On TNF Inhibitor Risks At DDW Meeting
Ocera Therapeutics is going against the tide of biologics for Crohn’s disease as its adsorptive carbon agent AST-120 enters Phase III in fistulizing Crohn’s disease.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product